Novartis Accounts Payable from 2010 to 2025
| NVS Stock | USD 111.09 1.04 0.93% |
Accounts Payable | First Reported 2000-12-31 | Previous Quarter 4.1 B | Current Value 4.6 B | Quarterly Volatility 1.5 B |
Check Novartis financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novartis' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.2 B, Interest Expense of 571.2 M or Selling General Administrative of 7.3 B, as well as many indicators such as Price To Sales Ratio of 2.76, Dividend Yield of 0.0247 or PTB Ratio of 2.35. Novartis financial statements analysis is a perfect complement when working with Novartis Valuation or Volatility modules.
Novartis | Accounts Payable |
Latest Novartis' Accounts Payable Growth Pattern
Below is the plot of the Accounts Payable of Novartis AG ADR over the last few years. An accounting item on the balance sheet that represents Novartis obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Novartis AG ADR are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Novartis' Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Novartis' overall financial position and show how it may be relating to other accounts over time.
| Accounts Payable | 10 Years Trend |
|
Accounts Payable |
| Timeline |
Novartis Accounts Payable Regression Statistics
| Arithmetic Mean | 4,985,725,841 | |
| Geometric Mean | 4,742,539,088 | |
| Coefficient Of Variation | 22.69 | |
| Mean Deviation | 653,126,968 | |
| Median | 5,403,000,000 | |
| Standard Deviation | 1,131,161,945 | |
| Sample Variance | 1279527.3T | |
| Range | 5B | |
| R-Value | 0.16 | |
| Mean Square Error | 1334439T | |
| R-Squared | 0.03 | |
| Significance | 0.55 | |
| Slope | 38,758,864 | |
| Total Sum of Squares | 19192910.2T |
Novartis Accounts Payable History
About Novartis Financial Statements
Novartis shareholders use historical fundamental indicators, such as Accounts Payable, to determine how well the company is positioned to perform in the future. Although Novartis investors may analyze each financial statement separately, they are all interrelated. The changes in Novartis' assets and liabilities, for example, are also reflected in the revenues and expenses on on Novartis' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Accounts Payable | 4.6 B | 4.2 B |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Novartis Stock Analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.